Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

PCRX has been the topic of a number of other research reports. Wedbush reiterated an “outperform” rating and issued a $89.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 19th. Mizuho reiterated a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. Canaccord Genuity set a $60.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 22nd. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday. Finally, Zacks Investment Research lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $54.50.

Pacira Pharmaceuticals (PCRX) opened at 37.225 on Friday. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $58.95. The stock’s 50 day moving average is $46.37 and its 200 day moving average is $45.57. The company’s market cap is $1.49 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. During the same quarter in the previous year, the firm posted $0.21 EPS. Pacira Pharmaceuticals’s revenue was up 1.9% on a year-over-year basis. Equities analysts anticipate that Pacira Pharmaceuticals will post ($0.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Stock Rating Lowered by ValuEngine” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/06/pacira-pharmaceuticals-inc-pcrx-stock-rating-lowered-by-valuengine.html.

In other news, CAO Kristen Marie Williams sold 21,041 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $50.86, for a total transaction of $1,070,145.26. Following the completion of the transaction, the chief accounting officer now directly owns 18,775 shares of the company’s stock, valued at approximately $954,896.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Scott Braunstein sold 768 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $33,269.76. Following the transaction, the senior vice president now directly owns 9,982 shares of the company’s stock, valued at $432,420.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,564 shares of company stock worth $2,506,682. Insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in PCRX. BlackRock Inc. increased its position in shares of Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after buying an additional 3,172,817 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock valued at $130,420,000 after buying an additional 112,853 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Pacira Pharmaceuticals by 0.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,608,847 shares of the company’s stock valued at $73,363,000 after buying an additional 5,166 shares during the last quarter. State Street Corp increased its position in shares of Pacira Pharmaceuticals by 2.7% in the first quarter. State Street Corp now owns 1,107,356 shares of the company’s stock valued at $50,499,000 after buying an additional 28,663 shares during the last quarter. Finally, Macquarie Group Ltd. increased its position in shares of Pacira Pharmaceuticals by 6.7% in the first quarter. Macquarie Group Ltd. now owns 1,074,770 shares of the company’s stock valued at $49,010,000 after buying an additional 67,321 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.